相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeted deep sequencing of DNA from multiple tissue types improves the diagnostic rate and reveals a highly diverse phenotype of mosaic neurofibromatosis type 2
Yu Teranishi et al.
JOURNAL OF MEDICAL GENETICS (2021)
Reliability and toxicity of bevacizumab for neurofibromatosis type 2-related vestibular schwannomas: A systematic review and meta-analysis
Jianwei Shi et al.
AMERICAN JOURNAL OF OTOLARYNGOLOGY (2021)
Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing
Zeng-Yun-Ou Zhang et al.
FRONTIERS IN GENETICS (2021)
Potential Molecular Biomarkers of Vestibular Schwannoma Growth: Progress and Prospects
Yu Zhang et al.
FRONTIERS IN ONCOLOGY (2021)
Efficacy of aspirin for sporadic vestibular schwannoma: a meta-analysis
Katrina Hannah D. Ignacio et al.
NEUROLOGICAL SCIENCES (2021)
Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis
Ryota Tamura
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
The SH3PXD2A-HTRA1 fusion transcript is extremely rare in Norwegian sporadic vestibular schwannoma patients
Peter Taule-Sivertsen et al.
JOURNAL OF NEURO-ONCOLOGY (2021)
HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence
Jianjiang Fu et al.
ONCOGENE (2021)
Tumor-Associated Macrophages in Vestibular Schwannoma and Relationship to Hearing
Eric Nisenbaum et al.
OTO OPEN (2021)
Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma
Masazumi Fujii et al.
CURRENT ONCOLOGY (2021)
The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications
Ryota Tamura et al.
MEDICAL ONCOLOGY (2020)
Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas
Ryota Tamura et al.
JOURNAL OF NEURO-ONCOLOGY (2020)
Therapy of Sporadic and NF2-Related Vestibular Schwannoma
Longping Yao et al.
CANCERS (2020)
Pathomechanisms in schwannoma development and progression
Dario-Lucas Helbing et al.
ONCOGENE (2020)
Schwannoma development is mediated by Hippo pathway dysregulation and modified b RAS/MAPK signaling
Zhiguo Chen et al.
JCI INSIGHT (2020)
Prostaglandin E2 and Cancer: Insight into Tumor Progression and Immunity
Federica Finetti et al.
BIOLOGY-BASEL (2020)
Bevacizumab Therapy of Neurofibromatosis Type 2 Associated Vestibular Schwannoma in Japanese Patients
Masazumi Fujii et al.
NEUROLOGIA MEDICO-CHIRURGICA (2020)
Sustained imaging response and hearing preservation with low-dose bevacizumab in sporadic vestibular schwannoma
Matthias A. Karajannis et al.
NEURO-ONCOLOGY (2019)
Gene therapy with apoptosis-associated speck-like protein, a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivo
Sherif G. Ahmed et al.
NEURO-ONCOLOGY (2019)
Gene Therapy for Human Sensorineural Hearing Loss
Yin Ren et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2019)
[68Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas
Maria Breun et al.
FRONTIERS IN ONCOLOGY (2019)
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma
Scott R. Plotkin et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2
Ryota Tamura et al.
NATURE COMMUNICATIONS (2019)
Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors
Shiyang Wang et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Gamma Knife radiosurgery for large vestibular schwannomas greater than 3 cm in diameter
Cheng-Wei Huang et al.
JOURNAL OF NEUROSURGERY (2018)
Activation of the HGF/c-Met axis in the tumor microenvironment: A multispecies model
Anna Konstorum et al.
JOURNAL OF THEORETICAL BIOLOGY (2018)
Aspirin Does Not Prevent Growth of Vestibular Schwannomas: A Case-Control Study
Samuel MacKeith et al.
LARYNGOSCOPE (2018)
Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models
Yingchao Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
CXCR4: A new player in vestibular schwannoma pathogenesis
Maria Breun et al.
Oncotarget (2018)
Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma
Jessica E. Sagers et al.
SCIENTIFIC REPORTS (2018)
Dual role of macrophage in tumor immunity
Ryota Tamura et al.
IMMUNOTHERAPY (2018)
PDGF regulated migration of mesenchymal stem cells towards malignancy acts via the PI3K signaling pathway
Sonia Salha et al.
CLINICAL HEMORHEOLOGY AND MICROCIRCULATION (2018)
Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells
Marisa A. Fuse et al.
MOLECULAR CANCER THERAPEUTICS (2017)
NLRP3 mutation and cochlear autoinflammation cause syndromic and nonsyndromic hearing loss DFNA34 responsive to anakinra therapy
Hiroshi Nakanishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
TIM-3 plays a more important role than PD-1 in the functional impairments of cytotoxic T cells of malignant Schwannomas
Zhao Li et al.
TUMOR BIOLOGY (2017)
Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells
Alejandra M. Petrilli et al.
ONCOTARGET (2017)
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Ping Wee et al.
CANCERS (2017)
Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response
Ryota Tamura et al.
BRAIN TUMOR PATHOLOGY (2017)
The genomic landscape of schwannoma
Sameer Agnihotri et al.
NATURE GENETICS (2016)
Mechanisms and regulation of endothelial VEGF receptor signalling
Michael Simons et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2016)
Bevacizumab in Neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation
Katrina A. Morris et al.
NEURO-ONCOLOGY PRACTICE (2016)
Interplay between VEGF-A and cMET signaling in human vestibular schwannomas and schwann cells
Sonam Dilwali et al.
CANCER BIOLOGY & THERAPY (2015)
Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas
Stephane Goutagny et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Neurofibromatosis Type 2
William H. Slattery
OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA (2015)
Schwann Cells: Development and Role in Nerve Repair
Kristjan R. Jessen et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2015)
Loud Noise Exposure and Acoustic Neuroma
James L. Fisher et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2014)
Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas
Matthias A. Karajannis et al.
NEURO-ONCOLOGY (2014)
Aspirin Intake Correlates With Halted Growth of Sporadic Vestibular Schwannoma In Vivo
Cherian K. Kandathil et al.
OTOLOGY & NEUROTOLOGY (2014)
Inflammatory and immune responses in the cochlea: potential therapeutic targets for sensorineural hearing loss
Masato Fujioka et al.
FRONTIERS IN PHARMACOLOGY (2014)
Targeting PI3K/Akt/mTOR signaling in cancer
Camillo Porta et al.
FRONTIERS IN ONCOLOGY (2014)
Regression of Schwannomas Induced by Adeno-Associated Virus-Mediated Delivery of Caspase-1
Shilpa Prabhakar et al.
HUMAN GENE THERAPY (2013)
Merlin, the NF2 Gene Product
Nives Pecina-Slaus
PATHOLOGY & ONCOLOGY RESEARCH (2013)
Multifaceted roles of PGE2 in inflammation and cancer
Masako Nakanishi et al.
SEMINARS IN IMMUNOPATHOLOGY (2013)
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy
Libero Santarpia et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Assessment of antiangiogenic effect of imatinib mesylate on vestibular schwannoma tumors using in vivo corneal angiogenesis assay Laboratory investigation
Ulas Yener et al.
JOURNAL OF NEUROSURGERY (2012)
Regulation of mTOR Complex 2 Signaling in Neurofibromatosis 2-Deficient Target Cell Types
Marianne F. James et al.
MOLECULAR CANCER RESEARCH (2012)
Merlin/NF2 Regulates Angiogenesis in Schwannomas through a Rac1/Semaphorin 3F-Dependent Mechanism
Hon-Kit Wong et al.
NEOPLASIA (2012)
Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2
Sylwia Ammoun et al.
NEURO-ONCOLOGY (2011)
AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas
Matthew L. Bush et al.
NEURO-ONCOLOGY (2011)
Cyclooxygenase-2 Supports Tumor Proliferation in Vestibular Schwannomas
Bujung Hong et al.
NEUROSURGERY (2011)
ErbB Expression, Activation, and Inhibition With Lapatinib and Tyrphostin (AG825) in Human Vestibular Schwannomas
Zana K. Ahmad et al.
OTOLOGY & NEUROTOLOGY (2011)
The NF2 Tumor Suppressor, Merlin, Regulates Epidermal Development through the Establishment of a Junctional Polarity Complex
Andrew B. Gladden et al.
DEVELOPMENTAL CELL (2010)
ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma
Sylwia Ammoun et al.
NEURO-ONCOLOGY (2010)
Erlotinib for Progressive Vestibular Schwannoma in Neurofibromatosis 2 Patients
Scott R. Plotkin et al.
OTOLOGY & NEUROTOLOGY (2010)
Hepatocyte growth factor protects endothelial cells against gamma ray irradiation-induced damage
Shun-ying Hu et al.
ACTA PHARMACOLOGICA SINICA (2009)
Human Schwannomas Express Activated Platelet-Derived Growth Factor Receptors and c-kit and Are Growth Inhibited by Gleevec (Imatinib Mesylate)
Joydeep Mukherjee et al.
CANCER RESEARCH (2009)
mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
Heidi A. Lane et al.
CLINICAL CANCER RESEARCH (2009)
Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells
Tina X. Lee et al.
EUROPEAN JOURNAL OF CANCER (2009)
Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors
Joannes F. M. Jacobs et al.
NEURO-ONCOLOGY (2009)
ErbB and Nrg: Potential molecular targets for vestibular schwannoma pharmacotherapy
Joni K. Doherty et al.
OTOLOGY & NEUROTOLOGY (2008)
The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: A preliminary study
J. Jason Clark et al.
OTOLOGY & NEUROTOLOGY (2008)
Expression of VEGF and its receptor genes in intracranial schwannomas
Toshio Uesaka et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification
Gareth R. Evans et al.
JOURNAL OF MEDICAL GENETICS (2007)
cDNA microarray analysis of vestibular schwannomas
DB Welling et al.
OTOLOGY & NEUROTOLOGY (2002)
分享论文
